Bioherent
Amount undisclosed
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Bioherent is currently valued at N/A as of July 17, 2025. The company has raised a total of $3.4M in funding.
Investment Perspective
Bioherent's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Bioherent Worth in 2025?
As of 2025, Bioherent is valued at N/A, based on the company's Early Stage VC funding round in July 17, 2025. This valuation positions Bioherent as one of the leading private companies in the sector.
Bioherent Valuation History
Bioherent's funding history demonstrates steady growth and investor confidence.
How Bioherent Valuation is Determined
Private company valuations like Bioherent's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Bioherent Valuation FAQs
Is Bioherent profitable?
Bioherent has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Bioherent's valuation compare to competitors?
Bioherent is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Bioherent IPO?
Bioherent has not announced plans for an initial public offering. Until an IPO, investors can access Bioherent shares through secondary market platforms.